Qnovia has secured a worldwide exclusive licence to a new antimicrobial peptide developed at the University of Virginia, ...

Sanofi has received European Commission approval to extend the indication of MenQuadfi to infants from six weeks of age, broadening access to protection against invasive meningococcal disease caused ...

Polpharma Biologics has announced that the FDA and EMA have accepted for review the BLA and MAA for PB016, a proposed ...

CelLBxHealth has announced the publication of an independent, peer‑reviewed study demonstrating that its Parsortix platform ...

Mission Therapeutics has agreed to divest its phase 2‑ready acute kidney injury candidate MTX652 to Australian renal ...

Johnson & Johnson has announced positive topline results from the phase 3 MonumenTAL‑6 study, which evaluated TECVAYLI and ...

There are currently no approved pharmacological treatments for cALD in the EU.

Lundbeck has received Fast Track designation from the U.S. FDA for Lu AH69593, its lead oral orexin 2 receptor agonist in ...

First patient randomised as study advances novel pan phosphate transporter inhibitor R1 Therapeutics has randomized the first ...

GSK has secured US FDA approval for Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1‑positive ...

Infinitopes has dosed the first patient with ITOP1, its lead investigational therapeutic cancer vaccine, marking the first ...

The CHMP has adopted a positive opinion recommending approval of Lynavoy for the treatment of cholestatic pruritus in adults ...